AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...
US FDA approves AstraZeneca’s Baxfendy, an aldosterone synthase inhibitor to treat adults with hypertension: Cambridge, UK Wednesday, May 20, 2026, 10:00 Hrs [IST] AstraZenecas ...
Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...
The coronavirus disease 2019 (COVID-19) pandemic caused millions of deaths throughout the world, which has provoked intense research into the pathogenetic mechanism behind this disease. A new study ...
Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease ...
A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
Increased levels of aldosterone are independently associated with a greater risk of type 2 diabetes, with the effects particularly notable in certain ethnic groups including African Americans and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results